Lantern Pharma Inc. Announces Proposed Public Offering of Common Stock

Dallas, Texas Mar 31, 2026 (EMWNews.com) – Lantern Pharma Inc. Announces Proposed Public Offering of Common Stock

Lantern Pharma Inc. (Nasdaq: LTRN) (the “Company”), a leading artificial intelligence (“AI”)-driven oncology company leveraging its proprietary RADR® platform to accelerate targeted cancer therapies, today announced that it intends to offer to sell shares of its common stock in a best-efforts public offering. All of the shares of common stock are to be sold by the Company.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. ThinkEquity is acting as sole placement agent for the offering.

The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-279718), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 24, 2024 and declared effective on June 10, 2024. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed or will be filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Lantern Pharma

Lantern Pharma (NASDAQ: LTRN) is an AI company focused on transforming the cost, pace, and timeline of oncology drug discovery and development. The Company’s proprietary AI and machine learning (ML) platform, RADR®, leverages approximately 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development.

Forward-Looking Statements

This press release contains forward-looking statements regarding the proposed public offering and the intended use of proceeds from the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed in the section “Risk Factors” included in the preliminary prospectus supplement, which will be filed with the SEC. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.